MacroGenics | MGNX - Selling And Administration Expenses


MacroGenics reported $9.9M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Amgen USD 1.94B 237M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Genmab DKK 144M 18M Jun/2025
Geron USD 39M 437K Sep/2025
Gilead Sciences USD 1.78B 425M Dec/2025
J&J USD 6.75B 831M Dec/2025
Karyopharm Therapeutics USD 27.19M 442K Dec/2024
MacroGenics USD 9.9M 600K Sep/2025
Merck USD 2.85B 215M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Xencor USD 87.78M 72.66M Sep/2025